SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

CASTELLAZZI, Massimiliano
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.618
AS - Asia 5.282
EU - Europa 3.321
SA - Sud America 825
AF - Africa 90
OC - Oceania 20
Continente sconosciuto - Info sul continente non disponibili 14
Totale 20.170
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.436
SG - Singapore 2.179
CN - Cina 1.614
BR - Brasile 711
IT - Italia 597
UA - Ucraina 529
HK - Hong Kong 524
DE - Germania 521
PL - Polonia 461
GB - Regno Unito 363
TR - Turchia 357
VN - Vietnam 251
FI - Finlandia 235
SE - Svezia 163
RU - Federazione Russa 140
CA - Canada 87
MX - Messico 81
ID - Indonesia 77
AT - Austria 65
IN - India 60
AR - Argentina 52
ZA - Sudafrica 52
FR - Francia 50
JP - Giappone 44
CZ - Repubblica Ceca 39
NL - Olanda 39
BE - Belgio 32
BD - Bangladesh 31
IQ - Iraq 25
ES - Italia 24
IR - Iran 23
AU - Australia 18
CO - Colombia 16
LT - Lituania 16
PY - Paraguay 14
UZ - Uzbekistan 13
KR - Corea 12
EC - Ecuador 11
A2 - ???statistics.table.value.countryCode.A2??? 8
AE - Emirati Arabi Uniti 8
EG - Egitto 8
KE - Kenya 8
SA - Arabia Saudita 8
UY - Uruguay 8
MA - Marocco 7
PT - Portogallo 7
EU - Europa 6
IE - Irlanda 6
KZ - Kazakistan 6
PK - Pakistan 6
RO - Romania 6
AZ - Azerbaigian 5
IL - Israele 5
VE - Venezuela 5
BG - Bulgaria 4
ET - Etiopia 4
HN - Honduras 4
JO - Giordania 4
NP - Nepal 4
PE - Perù 4
PH - Filippine 4
AO - Angola 3
CL - Cile 3
DO - Repubblica Dominicana 3
HU - Ungheria 3
KG - Kirghizistan 3
MY - Malesia 3
OM - Oman 3
TW - Taiwan 3
AL - Albania 2
BY - Bielorussia 2
CI - Costa d'Avorio 2
GR - Grecia 2
JM - Giamaica 2
LK - Sri Lanka 2
LV - Lettonia 2
LY - Libia 2
MD - Moldavia 2
NZ - Nuova Zelanda 2
SI - Slovenia 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
AM - Armenia 1
BA - Bosnia-Erzegovina 1
BB - Barbados 1
BH - Bahrain 1
BO - Bolivia 1
CH - Svizzera 1
DZ - Algeria 1
EE - Estonia 1
GD - Grenada 1
GE - Georgia 1
HR - Croazia 1
LA - Repubblica Popolare Democratica del Laos 1
LB - Libano 1
LU - Lussemburgo 1
MK - Macedonia 1
MN - Mongolia 1
NO - Norvegia 1
PA - Panama 1
Totale 20.165
Salva come PNG Salva come JPEG
Città #
Ashburn 1.169
Singapore 1.166
Woodbridge 1.121
Fairfield 905
Chandler 714
Houston 595
Beijing 572
Jacksonville 561
Santa Clara 524
Hong Kong 523
Warsaw 445
Ann Arbor 391
Seattle 330
Wilmington 328
Cambridge 294
Dallas 235
Izmir 223
Ferrara 219
New York 208
Los Angeles 203
Nanjing 187
Princeton 153
Munich 132
Milan 129
Boardman 108
Shanghai 92
San Diego 87
Ho Chi Minh City 79
Dearborn 77
São Paulo 73
Addison 65
Helsinki 59
Turku 57
Jakarta 56
Buffalo 55
Nanchang 55
Mexico City 54
Hanoi 52
Tianjin 52
Vienna 51
London 49
Shenyang 48
Bremen 47
Brooklyn 47
Changsha 42
Hebei 42
Jiaxing 42
The Dalles 42
Tokyo 42
Chicago 37
Norwalk 37
Denver 35
Phoenix 35
Stockholm 34
Hefei 33
Brussels 32
Chennai 32
Montreal 32
Orem 31
Brno 29
Johannesburg 28
Falls Church 26
Moscow 25
Toronto 25
Boston 24
Poplar 24
Atlanta 22
Redwood City 22
San Mateo 21
Zhengzhou 21
Dong Ket 20
Jinan 20
Ningbo 20
San Francisco 20
Auburn Hills 19
Bologna 19
Nuremberg 19
Orange 19
Rio de Janeiro 19
Guangzhou 18
Mountain View 17
Frankfurt am Main 16
Washington 16
Ankara 15
Belo Horizonte 15
Brasília 15
Columbus 15
Falkenstein 15
Kunming 15
Curitiba 12
Manchester 12
Tashkent 12
Amsterdam 11
Baghdad 11
Des Moines 11
Tappahannock 11
Verona 11
Charlotte 10
Hải Dương 10
Indiana 10
Totale 13.858
Salva come PNG Salva come JPEG
Nome #
Epstein-Barr Virus Specific Antibody Response in Multiple Sclerosis Patients during 21 Months of Natalizumab Treatment 387
Autophagy and mitophagy elements are increased in body fluids of multiple sclerosis-affected individuals 235
A Commentary on the Use of Epstein-Barr Virus Specific Antibodies as Biological Markers in Multiple Sclerosis 234
Multiple Sclerosis in Italy: A 40-Year Follow-Up of the Prevalence in Ferrara 231
Decreased Arylesterase activity of Paraoxonase-1 (PON-1) might be a common denominator of neuroinflammatory and neurodegenerative diseases 225
Evaluation of total, ceruloplasmin-associated and type II ferroxidase activities in serum and cerebrospinal fluid of multiple sclerosis patients 214
Biological markers in cerebrospinal fluid for axonal impairment in multiple sclerosis: acetylcholinesterase activity cannot be considered a useful biomarker 210
TIMP-1 resistant matrix metalloproteinase-9 is the predominant serum active isoform associated with MRI activity in patients with multiple sclerosis 209
Comparison of antibodies with amylase activity from cerebrospinal fluid and serum of patients with multiple sclerosis 206
Epstein-Barr virus and Multiple Sclerosis: in-depth analysis of the virus-specific antibody response at the time of diagnosis and during therapy 203
Timing of serum active MMP-9 and MMP-2 levels in acute and subacute phases after spontaneous intracerebral hemorrhage 202
Autophagy and mitophagy biomarkers are reduced in sera of patients with Alzheimer's disease and mild cognitive impairment 199
Chlamydia pneumoniaespecific intrathecal oligoclonal antibody response is predominantly detected in a subset of multiple sclerosis patients with progressive forms 198
Clinical and MRI disease activity in multiple sclerosis are associated with reciprocal fluctuations in serum and cerebrospinal fluid levels of soluble HLA class I molecules 197
Detection of antibodies directed against human herpesvirus 6 U94/REP in sera of patients affected by multiple sclerosis 196
Cerebrospinal fluid amounts of HLA-G in dimeric form are strongly associated to patients with MRI inactive multiple sclerosis 196
Epstein-Barr virus-specific antibody response in cerebrospinal fluid and serum of patients with multiple sclerosis 193
Comparison of DNA-Hydrolyzing Antibodies from the Cerebrospinal Fluid and Serum of Patients with Multiple Sclerosis 188
Emerging topics and new perspectives on HLA-G 187
Epstein-Barr virus-specific intrathecal oligoclonal IgG production in relapsing-remitting multiple sclerosis is limited to a subset of patients and is composed of low-affinity antibodies 185
Epidemiological health and social study on multiple sclerosis in the Ferrara province 182
Serum IgG against Simian Virus 40 antigens are hampered by high levels of sHLA-G in patients affected by inflammatory neurological diseases, as multiple sclerosis 178
Assessment of HIV-intrathecal humoral immune response in AIDS-related neurological disorders 178
Matrix metalloproteinase 9 as a marker of disease activity in multiple sclerosis 177
Interplay between Matrix Metalloproteinase-9, Matrix Metalloproteinase-2, and Interleukins in Multiple Sclerosis Patients 175
A Further Evidence Of Pathogenic Role Of Chlamydia Pneumoniae In Multiple Sclerosis 170
Correlation between auto/mitophagic processes and magnetic resonance imaging activity in multiple sclerosis patients 170
25-hydroxyvitamin D in cerebrospinal fluid from patients with multiple sclerosis 164
Cerebrospinal fluid analysis and the determination of oligoclonal bands 163
A new developed culture method efficiently supports the growth of Chamydia pneumoniae in PBMC and CSF samples from patients with Multiple Sclerosis 163
Intrathecal Soluble HLA-E Correlates with Disease Activity in Patients with Multiple Sclerosis and may Cooperate with Soluble HLA-G in the Resolution of Neuroinflammation. 162
An overview on the relationship between Epstein-Barr virus and multiple sclerosis 161
Potential relevance of cerebrospinal fluid and serum levels and intrathecal synthesis of active matrix metalloproteinase-2 (MMP-2) as markers of disease remission in patients with multiple sclerosis 160
Affinity distribution of anti-EBV IgG in the cerebrospinal fluid of patients with multiple sclerosis and in controls 158
A proteomic approach to detect gelatinases levels and their inhibitors in patients with neurological diseases 157
CEREBROSPINAL FLUID AND SERUM LEVELS OF ANTI-CHLAMYDIA PNEUMONIAE IGA IN PATIENTS WITH MULTIPLE SCLEROSIS 155
Antipsychotic drugs counteract autophagy and mitophagy in multiple sclerosis 154
Clinical and MRI activity are associated to elevated cerebrospinal fluid and serum levels and intrathecal synthesis of active matrix metalloproteinase-9 in multiple sclerosis patients 153
Serum Gelatinases Levels in Multiple Sclerosis Patients during 21 Months of Natalizumab Therapy 153
Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 are elevated in in multiple sclerosis patients with disease activity 150
Matrix metalloproteinase-9 activity detected in body fluids is the result of two different enzyme forms 149
DNA Sequences of Parachlamydia-like organisms in CSF of Patients with Neurological Disorders 149
Effect of pH on MMP-9 release by LPS-stimulated neutrophils 148
ERMES: EMILIA ROMAGNA MULTIPLE SCLEROSIS. REGIONAL NETWORK FOR IMPLEMENTING A BIOLOGICAL BANK TO IDENTIFY MARKERS OF DISEASE ACTIVITY RELATED TO CLINICAL VARIABLES Identification of a TIMP-1-resistant active MMP-9 in serum of Multiple Sclerosis patients 148
Matrix metalloproteinase-2 (MMP-2) generates soluble HLA-G1 by cell surface proteolytic shedding 148
Intrathecal levels of vitamin D and IgG in multiple sclerosis 144
Increased age and male sex are independently associated with higher frequency of blood-cerebrospinal fluid barrier dysfunction using the albumin quotient 143
Presence of detectable levels of soluble HLA-G molecules in CSF of relapsing-remitting multiple sclerosis: relationship with CSF soluble HLA-I and IL-10 concentrations and MRI findings 143
Quantification of CSF and serum levels and intrathecal synthesis of anti-EBV antibodies in patients with multiple sclerosis and with other neurological disorders. 143
Neurofilament ELISA validation 142
ERMES: EMILIA ROMAGNA MULTIPLE SCLEROSIS. REGIONAL NETWORK FOR THE IMPLEMENTATION A BIOLOGICAL BANK TO IDENTIFY MARKERS OF DISEASE ACTIVITY RELATED TO CLINICAL VARIABLES IN MS. 141
Investigation of the prevalence of antibodies against neurotropic polyomaviruses BK, JC and SV40 in sera from patients affected by multiple sclerosis 141
25 hydroxyvitamin D in cerebrospinal fluid from patients with multiple sclerosis during relapse and remission 140
Biomolecular and immunological diagnostic aspects of toxoplasmosis during AIDS. 139
Altered miRNA expression in T regulatory cells in course of multipla sclerosis 139
Multiplex Matrix Metalloproteinases Analysis in the Cerebrospinal Fluid Reveals Potential Specific Patterns in Multiple Sclerosis Patients 137
Analysis of MMP-9 in CSF and sera of patients with neurological diseases 136
Elevated CSF and serum levels and intrathecal synthesis of active MMP-2 in MS patients with no evidence of MRI disease activity 134
Timing of Serum Soluble HLA-G Levels in Acute and Subacute Phases After Spontaneous Intracerebral Hemorrhage 133
Altered miRNA expression in T regulatory cells in course of multiple sclerosis 129
An evaluation of quantitative env and qualitative pol rt-pcr detection of the multiple sclerosis (MS) -associated retrovirus in Europe 128
Intrathecal production of Chlamydia pneumoniae-specific high-affinity antibodies is significantly associated to a subset of multiple sclerosis patients with progressive forms 127
Matrix Metalloproteinases as a Pleiotropic Biomarker in Medicine and Biology 125
Decrease Paraoxonase-1 (PON-1) Activities in Neurodegenerative Diseases 124
INTRATHECAL PRODUCTION OF ACTIVE FORM OF MATRIX METALLOPROTEINASES-9 IN PATIENTS WITH MULTIPLE SCLEROSIS: PRELIMINARY RESULTS” 123
Specific antibodies reacting to JC polyomavirus capsid protein mimotopes in sera from multiple sclerosis and other neurological diseases-affected patients 123
Effect of HLA-G gene polymorphisms in the production of sHLA-G molecules in relapsing-remitting multiple sclerosis. 122
Increased Levels of Endothelin-1 in Cerebrospinal Fluid Are a Marker of Poor Visual Recovery after Optic Neuritis in Multiple Sclerosis Patients 122
Cerebrospinal fluid oligoclonal free light chain profiles in AIDS 121
Detection of Chlamydia pneumoniae-specific intrathecal oligoclonal antibody response in a subset of patients with progressive forms of multiple sclerosis 120
SERUM GELATINASES LEVELS IN MULTIPLE SCLEROSIS PATIENTS DURING 21 MONTHS OF NATALIZUMAB TREATMENT 120
CEREBROSPINAL FLUID AND SERUM LEVELS OF ANTI-CHLAMYDIA PNEUMONIAE IGA IN PATIENTS WITH MULTIPLE SCLEROSIS - ERMES: EMILIA ROMAGNA MULTIPLE SCLEROSIS. REGIONAL NETWORK FOR IMPLEMENTING A BIOLOGICAL BANK TO IDENTIFY MARKERS OF DISEASE ACTIVITY RELATED TO CLINICAL VARIABLES. 120
Kappa free light chains is a valid tool in the diagnostics of MS: A large multicenter study 119
CSF levels and soluble HLA-G and Fas molecules are inversely associated to MRI evidence of disease activity in patients with relapsing-remitting multiple sclerosis 118
Cerebrospinal fluid free Kappa and Lambda lights chains in MS. A qualitative analysis 117
Dimethyl Fumarate Treatment Reduces the Amount but Not the Avidity of the Epstein–Barr Virus Capsid-Antigen-Specific Antibody Response in Multiple Sclerosis: A Pilot Study 115
Intrathecal synthesis of interleukin-12 in multiple sclerosis 114
Matrix metalloproteinases (MMP): determination of different forms by different techniques may require different preanalytical strategies 113
Inflammation and axonal damage biomarkers in Multiple Sclerosis: new perspective on their role 113
CSF levels of soluble classical HLA-I and non-classical HLA-G molecules in relapsing-remitting multiple sclerosis and their association with CSF IL-10 concentrations and MRI findings. 113
Influence of different strategies of volume replacement on the activity of matrix metalloproteinases: an in vitro and in vivo study 112
Chlamydia pneumonia-specific CFS-restricted oligoclonal IgG bands are associated to a subset of patients with prosessive forms of multiple sclerosis. 110
null 110
Inverse association between CSF levels of solubile HLA-G and Fas molecules in MS patients with no evidence of MRI disease activity. 109
EBV-specific intrathecal oligoclonal antibody response in multiple sclerosis patients 109
Cerebrospinal fluid and serum levels and intrathecal production of active matrix metalloproteinase-9 (MMP-9) as markers of disease activity in patients with multiple sclerosis 109
null 109
N-acetylaspartate, glutammate and aspartate levels in multiple sclerosis cerebrospinal fluid. 108
Under the microscope: Focusing on Chlamydia pneumoniae infection and Multiple Sclerosis 106
Soluble HLA class I molecules intrathecal production in multiple sclerosis. 106
Ruolo dei micro RNA nel funzionamento delle cellule T immunoregolatorie CD4 e CD25 nell'ambito della Sclerosi Multipla 105
The Diagnostic Utility of Oligoclonal Bands in Multiple Sclerosis: A Time-Course Analysis 104
null 104
Matrix metalloproteinase-2 (MMP-2) immune functions via surface proteolytic shedding of HLA-G1 molecules 104
Potential role of soluble HLA-G molecules in multiple sclerosis 104
Gelatinases: enzymatic activity as potential biomarker in multiple sclerosis 104
Gelatinase: enzymatic activity as potential biomarker in multiple sclerosis 104
Herpesvirus Infections in KIR2DL2-Positive Multiple Sclerosis Patients: Mechanisms Triggering Autoimmunity 104
Extracellular pH modulates the release of Matrix Metalloproteinase-9 (MMP-9) by stimulated neutrophils and its activity. 104
null 102
Totale 14.928
Salva come PNG Salva come JPEG
Categoria #
all - tutte 97.064
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 996
Totale 98.060
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211.092 0 0 0 0 0 152 53 205 64 271 241 106
2021/20221.327 34 162 74 57 44 60 60 65 53 122 95 501
2022/20231.599 154 138 35 236 252 230 117 152 166 6 73 40
2023/2024956 79 88 45 25 101 187 27 85 35 25 28 231
2024/20253.531 76 79 275 142 447 302 117 159 679 385 494 376
2025/20265.249 999 379 835 1.331 1.489 216 0 0 0 0 0 0
Totale 20.445